The UC San Diego (UCSD) Moores Cancer Center (MCC) has a rich history as a matrix, NCI-designated comprehensive cancer center, now with 239 members from 28 UCSD departments. Peer-reviewed MCC funding is $118.3 million (direct costs), of which $33.2 million is from the NCI. An additional $15.6 million from non-peer-reviewed sources results in total direct-cost funding of $133.9 million. We have published over 4000 cancer-focused papers in the funding period (20% inter- or intra-programmatic; 10% in journals with an impact factor >15). MCC is surrounded by several other major life-science research institutes and 489 biotechnology companies in San Diego/La Jolla, the 2'' largest life-sciences cluster in the US. MCC is the only NCI-designated comprehensive cancer center in this region. MCC leverages this advantage to save lives by transforming cancer prevention, detection, and care (mission) and to make personalized cancer medicine a reality (vision). This is our first renewal application as a consortium center with partner San Diego State University (SDSU), thus formalizing long-standing, productive collaborations between MCC and SDSU. As designed, the MCC building 1) stimulates interdisciplinary collaboration between physicians and scientists in the Center's Divisions of Basic Science, Clinical Science, and Population Science, 2) assembles the extensive NCI-supported Shared Resources in a common, accessible site, and 3) acts as an academia-industry hub for translational cancer researchers within the public and private sectors of San Diego. The vast majority of members are in the MCC building or on the UCSD campus; others are in nearby La Jolla institutes. This application reports on six Research Programs: Cancer Biology and Signaling, Cancer Genomes and Networks, Hematologic Malignancies, Solid Tumor Therapeutics, Cancer Prevention, and Reducing Cancer Disparities. We also propose seven Shared Resources: Biorepository and Tissue Technology, Biostatistics, Genomics and Bioinformatics, Microscopy, Flow Cytometry, Transgenic Mouse, Diet and Physical Activity. All Programs and Resources reflect the scientific strengths and goals of the MCC. MCC is poised to leverage its exceptional basic and population sciences and San Diego-wide collaborations (academic and private-sector) in developing innovative science-based cancer prevention and treatment. This application summarizes our investments, recruitments, collaborations, organizational changes, plans, and progress toward this goal. CCSG funding advances the UCSD Moores Cancer Center mission to save lives by transforming cancer prevention, detection, and care, and vision to make personalized cancer medicine a reality. The Cancer Center places the highest priority on basic discovery and its translation (via leveraging San Diego's unique academia-industry environment) into major clinical advances that reduce the burden of cancer.

Public Health Relevance

CCSG funding advances the UCSD Moores Cancer Center mission to save lives by transforming cancer prevention, detection, and care, and vision to make personalized cancer medicine a reality. The Cancer Center places the highest priority on basic discovery and its translation (via leveraging San Diego's unique academia-industry environment) into major clinical advances that reduce the burden of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA023100-32
Application #
9478974
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Belin, Precilla L
Project Start
1996-07-01
Project End
2019-04-30
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
32
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of California, San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Dow, Michelle; Pyke, Rachel M; Tsui, Brian Y et al. (2018) Integrative genomic analysis of mouse and human hepatocellular carcinoma. Proc Natl Acad Sci U S A 115:E9879-E9888
Que, Xuchu; Hung, Ming-Yow; Yeang, Calvin et al. (2018) Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature 558:301-306
Murzin, Vyacheslav L; Woods, Kaley; Moiseenko, Vitali et al. (2018) 4? plan optimization for cortical-sparing brain radiotherapy. Radiother Oncol 127:128-135
Norton, Jeffrey A; Kim, Teresa; Kim, Joseph et al. (2018) SSAT State-of-the-Art Conference: Current Surgical Management of Gastric Tumors. J Gastrointest Surg 22:32-42
Ikeda, Sadakatsu; Tsigelny, Igor F; Skjevik, Åge A et al. (2018) Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. Oncologist 23:586-593
Buckley, Alexandra R; Ideker, Trey; Carter, Hannah et al. (2018) Exome-wide analysis of bi-allelic alterations identifies a Lynch phenotype in The Cancer Genome Atlas. Genome Med 10:69
Parish, Austin J; Nguyen, Vi; Goodman, Aaron M et al. (2018) GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers. Cancer 124:4080-4089
Xu, Selene; Thompson, Wesley; Ancoli-Israel, Sonia et al. (2018) Cognition, quality-of-life, and symptom clusters in breast cancer: Using Bayesian networks to elucidate complex relationships. Psychooncology 27:802-809
Tao, Li; Schwab, Richard B; San Miguel, Yazmin et al. (2018) Breast Cancer Mortality in Older and Younger Breast Cancer Patients in California. Cancer Epidemiol Biomarkers Prev :
Sagredo, Eduardo A; Blanco, Alejandro; Sagredo, Alfredo I et al. (2018) ADAR1-mediated RNA-editing of 3'UTRs in breast cancer. Biol Res 51:36

Showing the most recent 10 out of 862 publications